Navigation Links
John Garibotto Joins Cellnovo's Board of Directors
Date:6/20/2013

SWANSEA, England, June 21, 2013 /PRNewswire/ --

Cellnovo, the leading innovator in mobile diabetes management technology, announced today the appointment of John Garibotto as non-executive director.

Mr. Garibotto is a 20 year veteran of the medical device industry and has been instrumental in the development, formation, and financing of highly successful medical device companies including Insulet Corporation (IPO May 2007, Nasdaq: PODD) and TransVascular, Inc. (acquired by Medtronic in Sept '04).  He is presently the founder and Chief Technology Officer of Securus Medical Group, Inc.  Mr. Garibotto has earned a B.Sc. in Industrial Technology from the University of Massachusetts at Lowell and a Masters in Business Administration from Northeastern University.

"It is a real pleasure to welcome John as director," said Eric Beard, Cellnovo's Executive Chairman.  "John has vast experience in complex medical device development.  His expertise and guidance will be invaluable as we prepare to submit our mobile-diabetes management system for US approval."

"I'm delighted to join the board of this outstanding company," said John Garibotto.  "Cellnovo has developed a game-changing approach to the treatment and follow up of patients with type 1 diabetes.  I am very impressed by the mobile, real-time technology that Cellnovo have used for their system, which will undoubtedly address the many unmet needs of both patient and care teams."

About Cellnovo

A UK-based medical device company, Cellnovo develops an innovative mobile diabetes management system. Comprised of a mobile connected patch pump, mobile touchscreen handset/controller, blood glucose meter and applications, the Cellnovo system p
'/>"/>

SOURCE Cellnovo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
2. John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations
3. Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board
4. StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500
5. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
6. Dalia Dergham Joins Grace Century FZ LLC International Project Team
7. SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions
8. Elissa Guerra Joins Pursuit as VP of Client Solutions
9. Graphene joins the race to redefine the ampere
10. Provia Laboratories, LLC Joins Stoneham Chamber of Commerce in Massachusetts
11. Provonix Joins the Medrio Partner Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... 2014 -- A novel combination of microscopy and data ... Oak Ridge National Laboratory an unprecedented look at the ... and electrochemical properties. , The research team led ... surface of a perovskite manganite, a complex material that ... to understand surface behavior could benefit researchers who are ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... 24, 2014  Now available is a stem cell ... Regenerative Therapies , located in Guadalajara, Mexico ... people a new health option: stem cell therapies ... countless patients suffer from joint and muscle injuries due ... tears, torn rotator cuff, tennis elbow, and knee injuries. ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... WAYNE, Pa., May 15 Escalon Medical Corp.,(Nasdaq: ... quarter and,nine months ended March 31, 2008., For ... 18% to,$8,139,000 compared with $6,900,000 reported in the same ... sales in each of the,Company,s business units., Net ...
... biotechnology company that is focused on the development of,autologous (patient-derived) ... heart damage, today announced financial results for,the quarter ended March ... 19, 2008, the Company completed its initial public offering ... of approximately $5.8 million. The net ...
... Advisory Panel reacts to CMS final rule; ... identifies challenges, recommends strategies, ... Inc. and,the International Expert Wound Care Advisory Panel ... Improve Pressure,Ulcer Prevention and Treatment: Implications of the ...
Cached Biology Technology:Escalon(R) Reports Third Quarter Fiscal 2008 Results 2Escalon(R) Reports Third Quarter Fiscal 2008 Results 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 4Escalon(R) Reports Third Quarter Fiscal 2008 Results 5Escalon(R) Reports Third Quarter Fiscal 2008 Results 6Escalon(R) Reports Third Quarter Fiscal 2008 Results 7Escalon(R) Reports Third Quarter Fiscal 2008 Results 8Bioheart, Inc. Announces Financial Results for First Quarter 2008 2Bioheart, Inc. Announces Financial Results for First Quarter 2008 3Bioheart, Inc. Announces Financial Results for First Quarter 2008 4Bioheart, Inc. Announces Financial Results for First Quarter 2008 5Bioheart, Inc. Announces Financial Results for First Quarter 2008 6Bioheart, Inc. Announces Financial Results for First Quarter 2008 7International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 3
(Date:7/24/2014)... NY (July 24, 2014) Scientists at The ... are one step closer to creating a viable ... patient,s own cells. , For the first ... cells lines from skin samples of patients with ... an accelerated protocol to induce these stem cells ...
(Date:7/24/2014)... Citing many sobering examples of how wildlife loss leads ... article co-authored by Wildlife Conservation Society (WCS) Health ... Christopher Golden, calls for an interdisciplinary approach to tackle ... directly supports about 15% of the world,s people and ... world,s poor. It should come as no surprise that ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... acne (Propionibacterium acnes) will be the topic of the Denver ... University. As well as acne, this bacterium is responsible for ... diagnosis. Why are we not more aware of this versatile ... and boost the immune system: , Probiotics can ...
... Most college students in the United States do ... an essential skill in understanding the causes and ... the January issue of BioScience . The ... from Michigan State University, calls for a new way ...
... Scientists at Rothamsted Research, United Kingdom, in collaboration with ... Areas (ICARDA), Syria have developed a method of accounting ... trend refers to the variations in crop yield and ... trial. Usually plant breeders will grow several replicate ...
Cached Biology News:Probiotics, prebiotics and biofuel-producing bacteria 2College students lack scientific literacy, study finds 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
... Protein size: 325 Accession ... using peptide based assay: 1:1562500 ... 1.0g/ml in 5% skim milk / ... should be diluted in 1: 50,000 - ...
... 4503277 Accession Number: NP_001912.1 ... the nucleotide substrate for thymidylate synthetase. ... O = dUMP + NH 3 ... the Diseases: Benign Tumor; Leukemia; Escherichia ...
Active GST Protein...
Biology Products: